Brazil grants permission for clinical trial of new Chinese vaccine
2021-04-22 17:24
A woman holds a small bottle labeled with a Coronavirus COVID Vaccine sticker and a medical syringe in this illustration taken October , . PhotoAgencies    RIO DE JANEIRO  Brazils National Health Surveillance Agency Anvisa has authorized clinical trials of a new COVID vaccine developed by Chinas Sichuan Clover Biopharmaceuticals, according to official statement, Reuters reported on Monday. Anvisa said the company was authorized to conduct Phase II and III trials in Brazil, and Sichuan Clover is planning to test the vaccine on , volunteers in Latin America, South Africa, Belgium, China, Spain, Poland and the United Kingdom, said the report. On the same day, CNBC reported that Chinas CanSino Biologics will be starting clinical trials next week for a COVID vaccine that is administered through inhalation. An inhaled vaccine could theoretically provide additional protection by activating antibodies in the airways, the companys cofounder and Chief Executive Xuefeng Yu told CNBC.